Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up – What’s Next?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $104.67, but opened at $114.50. Palvella Therapeutics shares last traded at $113.2750, with a volume of 4,910 shares.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on PVLA shares. HC Wainwright lifted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Mizuho lifted their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Finally, Stephens reissued an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Stock Down 1.6%

The firm’s fifty day moving average price is $120.96 and its two-hundred day moving average price is $107.68. The stock has a market capitalization of $1.63 billion, a PE ratio of -27.23 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Insider Transactions at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Large investors have recently added to or reduced their stakes in the business. Aberdeen Group plc bought a new stake in Palvella Therapeutics during the third quarter valued at approximately $3,212,000. First Light Asset Management LLC bought a new position in shares of Palvella Therapeutics in the third quarter worth approximately $33,949,000. Suvretta Capital Management LLC boosted its position in shares of Palvella Therapeutics by 15.1% in the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after purchasing an additional 107,937 shares during the period. Apis Capital Advisors LLC bought a new position in shares of Palvella Therapeutics in the third quarter worth approximately $627,000. Finally, Jennison Associates LLC boosted its position in shares of Palvella Therapeutics by 262.4% in the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after purchasing an additional 280,573 shares during the period. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.